Eligibility Criteria

Seattle Cancer Care Alliance (SCCA)

Seattle Cancer Care Alliance (SCCA)

Protocol 1410

Treatment with Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with Human Immunodeficiency Virus-1 Using a Non-Ablative Conditioning Regimen Containing Total Body Irradiation in Combination with Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil

Purpose

The purpose of the treatment on this study is to replace bone marrow cells with healthy cells donated by a person with a healthy immune system. The new bone marrow or hematopoietic stem cells have the ability to grow into new blood and immune systems. We believe that HAART may give us a new way to help control the HIV and prevent it from infecting the new bone marrow cells. We will monitor the level of HIV in the latent reservoir to determine whether HAART drugs can continue to control or even reduce HIV after hematopoietic stem cell transplantation (HSCT).

Major eligibility criteria

  1. Patients with a hematologic malignancy in remission treatable with HSCT, who:
    a. have been on HAART for at least one month, and
    b. have a HIV load <5000 copies/ml.
  2. Or, Patients without malignancy who meet these criteria:
    a. have been treated with more than one HAART regimen for at least six continuous months, and
    b. have a HIV load <50 copies/ml, and
    c. have a CD4 count <100 cells/ml.
  3. Patients must have an HLA-matched donor.
  4. Patients must be <65 years old.

Contact

For more information, contact the Clinical Coordinator Office at the Seattle Cancer Care Alliance (1-800-804-8824) and reference protocol number 1410.

Protocol 2212

Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution after Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV

Purpose

We are performing this study because some patients with HIV also have a serious blood disorder, which needs to be treated with HCT. The study will monitor patients given HCT so that we will learn whether there are serious problems due to the HIV. The purpose of the study is to find out what happens to the latent HIV reservoir in patients who have HIV and who are given HCT for treatment of their leukemia or lymphoma. This study will offer a unique chance to understand the effect of intensive chemo/radiotherapy, and in many cases allogeneic grafts, on clearance of latently infected resting CD4+ cells and reconstitution of HIV-specific immune responses.

Major eligibility criteria

  1. Patients with a hematologic malignancy treatable with HSCT, who:
    a. have been on HAART for at least one month, and
    b. have a HIV load <5000 copies/ml.
  2. Patients must be able to donate autologous peripheral blood stem cells or have an HLA-matched donor.
  3. Patients must be <66 years old for allogeneic HCT, or <76 years old for autologous HCT.
  4. Patients must not have poor health, such as liver disease, kidney disease, lung disease, heart disease, or active infections.

Contact

For more information, contact the Clinical Coordinator Office at the Seattle Cancer Care Alliance, (1-800-804-8824) and reference protocol number 2212.

Protocol 2485

High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-Infected Patients. (BMT-CTN Protocol 0803 (AMC Protocol 071)

Purpose

We are performing this study to determine if HIV-positive patients with lymphoma will benefit from autologous peripheral blood stem cell (PBSC) transplant. Patients donate autologous PBSC, which are frozen until later use. Patients are given high-dose chemotherapy to treat lymphoma, and then are given back their own PBSC after receiving chemotherapy – also referred to as conditioning therapy.

Major eligibility criteria

  1. Patients with diffuse large B-cell lymphoma, composite lymphoma with >50% diffuse large B-cell lymphoma, mediastinal B-cell lymphoma, immunoblastic, plasmablastic, Burkitts or Burkitt-like lymphoma, transformation from follicular lymphoma, or classical Hodgkins lymphoma.
  2. Patients must be at least 15 years old.
  3. Patients must not have had more than 3 prior courses of chemotherapy.
  4. Patients must not have poor health, such as liver disease, kidney disease, lung disease, heart disease, or active infections.
  5. Patients must be able to donate sufficient numbers of autologous peripheral blood stem cells.
  6. Patients must be on HAART, with: a) Undetectable HIV viral load (VL<50 copies); or b) If viral load is VL detectable, must have an evaluation and approval by a Harborview Madison Clinic HIV specialist.

Contact

For more information, contact the Clinical Coordinator Office at the Seattle Cancer Care Alliance, (1-800-804-8824) and reference protocol number 2485.